Evaluation of the Dexcom G6 Continuous Glucose Monitoring System With a Non-Interferent Sensor

NCT ID: NCT03087877

Last Updated: 2018-12-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-03

Study Completion Date

2017-03-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to demonstrate effectiveness of the G6 sensor membrane, in preventing acetaminophen's interference effect on glucose sensing.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The interference effect of the sensor will be evaluated by comparing the bias in the glucose values exhibited from the G6 CGM system after administration of acetaminophen. Bias will be evaluated by comparing CGM values to a laboratory referenceusing venous sample measurements.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

The system will be blinded to the user, i.e. no glucose values will be displayed to the subject during the study duration.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CGM Users

Prospective, non-randomized, single-arm. Continuous Glucose Monitoring. Acetaminophen challenge is the intervention.

Group Type OTHER

Acetaminophen Challenge (G6 CGM)

Intervention Type DEVICE

Evaluation of acetaminophen effect on CGM glucose sensing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acetaminophen Challenge (G6 CGM)

Evaluation of acetaminophen effect on CGM glucose sensing

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages 18 or older
* Diagnosis of diabetes

Exclusion Criteria

* Pregnancy
* Known gastroparesis
* Abnormal liver function
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

DexCom, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Price, MD

Role: STUDY_DIRECTOR

DexCom, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AMCR

Escondido, California, United States

Site Status

William Sansum Diabetes Center

Santa Barbara, California, United States

Site Status

Diablo Clinical Research

Walnut Creek, California, United States

Site Status

Rainier Clinical Research Center Inc

Renton, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PTL902020

Identifier Type: -

Identifier Source: org_study_id